VEGFA mRNA for regenerative treatment of heart failure

Anna Collèn, Nils Bergenhem, Leif Carlsson, Kenneth R. Chien, Stephen Hoge, Li-Ming Gan and Regina Fritsche-Danielsson

The recent successful development of COVID-19 vaccines using mRNA technology clearly shows the great potential for this novel modality. In addition to prophylactic mRNA vaccines for infectious diseases and therapeutic mRNA vaccines for cancer, there is substantial interest in mRNA therapeutics. The first potential 'secreted protein' mRNA drug — designed to deliver vascular endothelial growth factor A (VEGF-A) to induce regenerative angiogenesis in patients with cardiovascular disease — was advanced into phase I trials in 2016 (NCT02935712) (Mullard, A. mRNA-based drug approaches phase I milestone. Nat. Rev. Drug Discov, 15, 595 (2016)). Here, we highlight the history and clinical development of this agent (known as AZD8601), with the aim of providing insights that may be useful for the further development of mRNA therapeutics.

Therapeutic rationale

VEGF-A has long been recognized as a potential vascular and proliferative regenerative therapeutic in patients with ischaemic heart disease. However, unlocking its therapeutic potential has been confounded by the challenges of the relatively short half-life of the systemically administered protein, side effects from chronic long-term exposure and the delivery challenges to the intact heart in vivo to achieve the desired therapeutic threshold.

The modified mRNA technology used in COVID-19 vaccines also holds great potential for therapeutic applications requiring controlled spatial and temporal delivery of parasite factors such as VEGF-A. This potential supported the investigation of VEGFA mRNA to induce therapeutic angiogenesis and proliferation in the context of heart disease.

Drug delivery and pharmacokinetics

Given the concern that VEGFA mRNA formulated in lipid-based carriers for efficient spontaneous transfection of cardiomyocytes when injected directly into the myocardium of the heart, and caused no activation of the innate immune system in multiple species. Furthermore, VEGF-A protein expression by cardiomyocytes has a transient and pulse-like profile following intracardial administration of mRNA formulated in a simple citrate saline buffer solution. Following intracardiac injection of 100 μg of VEGF-A mRNA in rats, the Cmax of VEGF-A (6,340 pg per tissue sample) was 6 hours and the terminal half-life was 28 hours. This more transient pharmacokinetic profile differs fundamentally from that of gene therapy modalities and may finally unlock the therapeutic potential of VEGF-A.

Effects in animal models

VEGFA mRNA induces cardiovascular regeneration by increasing the capillary density in the injured muscle. We investigated the therapeutic potential of VEGFA mRNA in mouse, rat and pig models of myocardial infarction. In rats, direct intramyocardial injection of VEGFA mRNA at the same time as induction of myocardial infarction led to a significant increase in left ventricular ejection fraction (LVEF) 1 week after administration, as assessed by cardiac MRI. In a pig model, VEGFA mRNA was injected into ~20 sites across the peri-infarct region 7 days after induction of myocardial infarction. Two months after treatment, LVEF showed a statistically significant improvement in the VEGFA mRNA group compared with the saline control group (52% versus 47%). We also noted improvement in haemodynamic parameters and myocardial compliance in pigs treated with VEGFA mRNA. Histological examination revealed increased capillary and arteriole density and reduced fibrosis in the peri-infarct region of pigs treated with VEGFA mRNA compared with control animals.

Studies in humans

The first VEGFA mRNA clinical trial was a randomized phase I study in otherwise healthy volunteers with type 2 diabetes mellitus (NCT02935712), aiming to assess safety and tolerability and provide proof of the therapeutic principle. Injection of VEGFA mRNA formulated in citrate saline buffer induced VEGF-A production in humans without causing serious side effects. Skin microdialysis revealed that local VEGF-A levels at mRNA-treated injection sites were increased compared with placebo. Injection of 360 μg of VEGFA mRNA (the highest dose evaluated) resulted in VEGF-A levels of 300 pg ml⁻¹, peaking at 3.5–5 hours and sustained for 24 hours, compared with 170 pg ml⁻¹ for placebo. By contrast, systemic VEGF-A levels were not elevated and were consistent with previously published normal levels. Treatment was well tolerated, and the only adverse events causally related to VEGFA mRNA were mild injection site reactions.

Conducting the phase I study in patients with type 2 diabetes mellitus, who tend to have impaired blood flow in multiple organs, including the skin, enabled detection of increases in skin blood flow to provide proof of the principle that VEGFA mRNA may have potentially beneficial angiogenic effects. Laser Doppler fluximetry and imaging revealed a twofold enhancement in basal skin blood flow 4 hours after administration, which was sustained 7 days after administration, at VEGFA mRNA-treated injection sites compared with placebo-treated sites. The magnitude of this improvement was similar to the magnitude of the difference in basal blood flow between patients with type 2 diabetes mellitus and healthy volunteers in the previous methodological study, suggesting transient normalization of basal skin blood flow at VEGFA mRNA-treated injection sites. These findings confirmed the therapeutic potential of VEGFA mRNA and supported further clinical development.

The second clinical trial of VEGFA mRNA was a phase Ia safety and exploratory efficacy study in patients with reduced LVEF who were undergoing coronary artery bypass grafting (NCT03370887; known as EPICCURE). In this randomized, double-blind trial, patients received 30 epidermal injections of VEGFA mRNA or placebo in a short extension of the surgical procedure. These injections were targeted to specific myocardial regions via a personalized injection map created for each patient using [¹⁸F]-water PET imaging of myocardial blood flow. For each injection, the volume was 0.2 ml and the dose was 0.1 mg, resulting in a total dose of 3 mg of VEGFA mRNA.

The planned enrolment for the phase Ia EPICCURE study was 24 patients, but the study was terminated after 11 patients had been randomized because of slow recruitment rates. The slow recruitment was due to several
factors. Only a few countries have approved isotope labelling facilities for $^{15}$O-water PET, and the study was conducted in specific sites in Finland and Germany where the number of patients undergoing elective coronary artery bypass grafting is limited. In addition, after the COVID-19 pandemic started, the frequency of elective surgery was substantially reduced. At the time of writing, all these patients have completed the study and no deaths or serious treatment-related adverse events have occurred. Preliminary data on adverse events, echocardiography and clinical laboratory findings indicate no safety signals of concern. High-level results presented at the American Heart Association conference in November 2021 showed that the primary endpoint of safety and tolerability was met, and exploratory efficacy analyses support further clinical development to benefit patients with heart failure.

**Conclusion**

We have presented the development journey of one of the first mRNA therapeutic molecules to enter clinical trials (FIG. 1). Its early clinical development has built on a strong platform of preclinical experiments in several animal species, and it has the potential to expand into further clinical development to benefit patients with heart failure.

**Competing interests**

A.C., N.B., L.-M.G. and R.F.D. are employees of AstraZeneca and may own stock or stock options. S.H. is an employee of Moderna, Inc. and holds stock or stock options. K.R.C. is an advisor and chair of the External Science Panel for AstraZeneca and a member of the Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Center in Huddinge, and receives support for these services, as well as research support through the Karolinska Institutet Center. He is also a co-founder and equity holder of Moderna, Inc.

**Peer review information**

*Nature Reviews Drug Discovery* thanks the anonymous reviewers for their contribution to the peer review of this work.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.